ArticleBlood cell therapy2026
Early Secondary Graft Failure After Complete Donor Chimerism with Autologous Recovery Following Haploidentical HSCT for Relapsed B-ALL.
Article in Blood cell therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Secondary graft failure after initial donor engraftment is a rare complication of allogeneic hematopoietic stem cell transplantation (HSCT). We report a 47-year-old man with Philadelphia chromosome-negative B-cell acute lymphoblastic leukemia (B-ALL) who underwent haploidentical sibling peripheral blood HSCT after second complete remission. Neutrophil engraftment occurred by Day +14 with platelet engraftment by Day +18. Beginning Day +22, recurrent fever with progressive cytopenias developed. Day +30 peripheral blood short tandem repeat (STR) analysis showed complete donor chimerism; however, cytomegalovirus (CMV) DNAemia increased to 3,736 IU/mL, prompting therapeutic valganciclovir. Bone marrow biopsy on Day +37 showed hypocellular marrow without residual disease, although bone marrow X/Y fluorescence in situ hybridization (FISH) demonstrated 100% XY signals despite a female donor, indicating graft loss. Septic shock developed on Day +48. Management included growth factors, temporary tacrolimus withdrawal, antibiotics, granulocyte infusions, and a stem cell boost on Day +62. Repeat peripheral blood chimerism by Day +95 showed complete recipient genotype, confirming secondary graft failure with autologous reconstitution. Follow-up through Day +183 confirmed sustained autologous hematopoiesis with no relapse or graft-versus-host disease (GVHD). This case highlights an uncommon transition from donor-type marrow failure to autologous recovery and underscores the importance of bone marrow-based chimerism monitoring in cytopenic post-transplant patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.